Effects of empagliflozin on cardiac and vascular hemodynamic markers by subgroups of age, sex and hypertension in patients with T2DM and high CV risk: EMPA-reg outcome.

Back

ESC Premium Access

Effects of empagliflozin on cardiac and vascular hemodynamic markers by subgroups of age, sex and hypertension in patients with T2DM and high CV risk: EMPA-reg outcome.

Session: Optimising cardiovascular pharmacotherapy

Topic: Drug therapy

Speaker: Doctor O. Johansen (Hovik, NO)

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Doctor Odd Erik Johansen

Nestle Health Science, Hovik (Norway)

0 follower

7 more presentations in this session

Beneficial effect of beta-blockers on clinical outcomes persist after discontinuation in patients with ST elevation myocardial infarction?

Speaker: Assistant Professor J. Park (Suwon, KR)

Monocyte chemoattractant protein-1 level and (-75)G/A polymorphism of APOA1 gene predict response and resistance to intensive statin therapy in very high cardiovascular risk patients.

Speaker: Professor S. Villevalde (Saint Petersburg, RU)

Efficacy of evinacumab in homozygous familial hypercholesterolemia patients with null or non-null LDL-receptor mutations and on various background therapies

Speaker: Doctor G. Hovingh (Amsterdam, NL)

Access

Abstract

Riociguat ameliorates right ventricular function in patients with pulmonary hypertension.

Speaker: Assistant Professor M. Murata (Kanagawa, JP)

The beneficial effects of renin angiotensin system blockades on two years outcomes in coronary artery ectasia patients

Speaker: Doctor Y. Wang (Beijing, CN)

Access

Abstract

Access the full session

Optimising cardiovascular pharmacotherapy

Speakers: Doctor O. Johansen, Assistant Professor J. Park, Professor S. Villevalde, Doctor G. Hovingh, Assistant Professor M. Murata...

Access

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources